How soon does Wegovy start to suppress appetite — and what shapes the timeline?

The first few weeks: early signals, not the full picture

The 0.25mg starting dose is not where the appetite effect lives. Its job is to let your body adjust to semaglutide (managing the nausea, indigestion and fatigue that are most common at the outset) rather than to deliver peak suppression. Many people in the first fortnight describe feeling slightly less hungry, or noticing that the urge to snack has quietened a little. That is real, but it is a preview rather than the main event.

Semaglutide works by activating GLP-1 receptors in the gut and brain, slowing the rate at which food leaves the stomach and signalling fullness to appetite-regulating centres in the brain. At 0.25mg those signals are present but relatively gentle. How Wegovy suppresses appetite is worth reading if you want the mechanism in more detail, and if you are curious whether Wegovy only suppresses appetite or whether it works in other ways too, that is covered there as well.

A practical thing many people find useful at this stage: before each meal, ask yourself how hungry you genuinely are on a scale of one to ten, and note whether that number is shifting week on week. It takes under a minute and gives you something concrete to bring to your prescriber review.

Months two to four: appetite changes become more consistent

The titration schedule moves the dose from 0.25mg to 0.5mg after roughly four weeks, then to 1.0mg, and so on upward toward 2.4mg. Each step tends to deepen the appetite effect. By the time most people reach 1.0mg or 1.7mg, the change feels more reliable: smaller portions feel satisfying, interest in food between meals reduces, and the impulse to eat out of habit or boredom often fades.

This is also when people start making real decisions about what to eat on Wegovy, because understanding how Wegovy suppresses appetite makes clear that the signal alone does not guarantee good nutritional choices, it just makes it easier to eat less. Protein adequacy, fibre and hydration matter considerably during this phase, and your prescriber or a dietitian is the right person to help you plan.

Side effects, mainly nausea and digestive discomfort, are often most noticeable after a dose step and tend to settle within a week or two. The Wegovy treatment overview sets out the full dose schedule and what to expect at each stage, as described in the licensed prescribing information.

When the appetite effect does not seem to be arriving

A smaller group of people reach the maintenance dose and feel the suppression is weaker than expected. There are several reasons this can happen. Eating very quickly outpaces the satiety signal, which takes twenty minutes or so to register after food reaches the stomach. Very energy-dense or highly processed foods can partially bypass the delayed-emptying mechanism. Sleep deprivation and high stress both elevate ghrelin (the hunger hormone), which can compete with semaglutide's signals.

It is also worth knowing that Wegovy does more than suppress appetite (it has effects on reward pathways, liver function and cardiovascular risk) so even if the hunger reduction feels subtle, other effects may be at work. Wegovy's effects beyond appetite covers this in full.

If you find Wegovy is not suppressing your appetite as expected after several weeks at a stable dose, that is a conversation for your prescriber, not a reason to change the dose yourself. The NHS patient information for semaglutide on NHS.uk outlines what to raise with your healthcare team and when to seek urgent help.

Making a decision: is the timeline working for you?

The honest framing is this: Wegovy's appetite suppression is not a switch that flips in week one. It is a gradual pharmacological shift that takes most people three to five months to experience fully, roughly the time to reach and stabilise on the maintenance dose. Expecting strong suppression from the starter dose, and concluding treatment is not working because it is not there yet, is the most common reason people lose confidence too early.

Clinical trials showing around 15% average weight reduction over 68 weeks (the figures from the STEP 1 study published in the New England Journal of Medicine) reflect the full titration period, not just the first weeks. The trajectory matters as much as the destination.

If you are wondering whether Wegovy is the right fit for your situation, or whether something like tirzepatide (Mounjaro) might suit you better, that question belongs in a clinical consultation. Exploring the treatment options is a useful starting point, and starting a free consultation connects you with a prescriber who can review your full picture and advise honestly.